← All trials

NCT05723692

Phase 1Interventional

Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.

View on ClinicalTrials.gov ↗

Timeline

Start date
Jan 17, 2023
Primary completion
Aug 30, 2023
Completion date
Dec 31, 2023
First posted
Feb 13, 2023
Last posted
Oct 18, 2023
Enrollment
64
Arms / groups
2 / —
Source
AACT · ctgov ingestion

Sponsors

  • AltruBioLead sponsor
  • ICONCollaborator
  • ICONOverall official - principal investigator

Drugs studied

Indications studied

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.